- In April 2023, Eli Lilly and Company launched a strategic initiative in South Africa aimed at improving access to affordable insulin therapies for diabetic patients in underserved regions. This initiative underscores the company’s dedication to equitable healthcare by expanding its low-cost insulin programs and educational outreach to support proper diabetes management. By leveraging its global footprint and patient-centric approach, Eli Lilly is reinforcing its leadership in the rapidly growing global insulin market
- In March 2023, Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced the successful rollout of its interchangeable biosimilar insulin glargine (Semglee) in key global markets, including the U.S. and parts of Europe. This biosimilar offers a more affordable alternative to branded insulins, enhancing patient access to long-acting insulin therapies. The move aligns with global efforts to reduce diabetes care costs and broaden treatment availability
- In March 2023, Novo Nordisk announced the expansion of its insulin production facility in Clayton, North Carolina, U.S., to meet the surging global demand for both human insulin and insulin analogs. The investment reflects the company’s long-term commitment to manufacturing scale and supply chain reliability, ensuring uninterrupted access to life-saving insulin therapies for millions of patients worldwide
- In February 2023, Sanofi partnered with the Indian government to support national diabetes management efforts by donating thousands of insulin pens and launching awareness campaigns across rural areas. This public-private collaboration is designed to address the rising burden of diabetes and promote early diagnosis and treatment through accessible insulin delivery solutions
- In January 2023, Wockhardt Ltd. unveiled its new line of recombinant human insulin products in emerging markets across Latin America and Southeast Asia. The launch is part of the company’s broader global strategy to deliver cost-effective diabetes care solutions and expand its presence in high-growth insulin markets. The initiative demonstrates Wockhardt’s continued commitment to innovation, affordability, and accessibility in diabetes management
